Chutes and Ladders

Latest Headlines

Latest Headlines

Drew Fromkin takes the helm at Langer's Blend Therapeutics

Blend Therapeutics, which was founded by Omid Farokhzad and MIT's Robert Langer, has named Drew Fromkin as its new CEO.

Kathrin Jansen to head Pfizer vaccines R&D

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Head of Indian pricing authority pushed out after price hikes

The head of India's National Pharmaceutical Pricing Authority was removed from the job just a week after his agency allowed the prices of 509 essential drugs to increase by 3.8%. But Chairman Injeta Srinivas' removal more likely was the result of complaints from the pharma and devices industries, which objected to recent moves he made that cost them money.

Kathrin Jansen named head of Pfizer vaccine R&D

Pfizer has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, New York research site.

South Korea names first woman to head food and drug safety ministry

Seunghee Kim, a veteran member of South Korea's Ministry of Food and Drug Safety, has been named to become its first female minister. Kim has a pharmacology degree from Seoul National University and a doctorate in biochemistry from Notre Dame.

UPDATED: CRISPR-Cas9 pioneer starts recruiting R&D group in Cambridge hub

CRISPR Therapeutics--which was founded in Switzerland by Emmanuelle Charpentier, one of the pioneers in the field--has hired Alexion vet Bill Lundberg to head up its R&D operations in Cambridge, MA.

CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals

Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But thanks to his penchant for risk-taking, in the 5-plus years he's been with the German pharma, he's gotten plenty done already.

Cipla India head Goel resigns just over a year into job

The head of Cipla's India operations has resigned from his post just more than a year after joining from GlaxoSmithKline in January last year, the company said in an email to FiercePharmaAsia.

Genentech begins search for bioinformatics chief after Gentleman leaves for 23andMe

The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.

Homeland Security names program manager for new NBAF facility in Kansas

The Department of Homeland Security has named Marty Vanier of Kansas State University as the senior program manager for strategic partnership and development for the new National Bio and Agro-Defense Facility (NBAF) expected to by completed by 2018.